These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 29974949

  • 21. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, Delia M, Cumbo C, Orsini P, Specchia G, Albano F.
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K.
    Leuk Res; 2018 Feb; 65():74-79. PubMed ID: 29310021
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R, Ismail SM, Mohd Yunus N, Sulong S, Husin A, Abdullah AD, Hassan R.
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [Abstract] [Full Text] [Related]

  • 26. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
    Gui X, Zhang Y, Pan J, Qiu H, Cen J, Xue Y, Chen S, Shen H, Yao L, Zhang J, Wu Y, Chen Y.
    Leuk Lymphoma; 2015 Dec; 56(12):3343-7. PubMed ID: 25962435
    [Abstract] [Full Text] [Related]

  • 27. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY, Noh H, Choi SY, Lee SE, Kim SH, Kee KM, Yoo HL, Lee MY, Kang KH, Suh JH, Yang SY, Jang EJ, Lee JI, Kim DW.
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [Abstract] [Full Text] [Related]

  • 28. The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias.
    Stella S, Gottardi EM, Favout V, Barragan Gonzalez E, Errichiello S, Vitale SR, Fava C, Luciano L, Stagno F, Grimaldi F, Pironi L, Sargas Simarro C, Vigneri P, Izzo B.
    Int J Mol Sci; 2019 Dec 04; 20(24):. PubMed ID: 31817063
    [Abstract] [Full Text] [Related]

  • 29. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y, Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, Hsiao PC, Chen CC, Wang PN, Shih LY.
    Cancer Sci; 2022 Oct 04; 113(10):3518-3527. PubMed ID: 35869805
    [Abstract] [Full Text] [Related]

  • 30. The e1a3 BCR-ABL1 fusion transcript in Philadelphia chromosome-positive acute lymphoblastic leukaemia: a case report.
    Chen Z.
    Hematology; 2023 Dec 04; 28(1):2186040. PubMed ID: 36912524
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.
    Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.
    Anticancer Res; 2019 Jul 04; 39(7):3949-3954. PubMed ID: 31262926
    [Abstract] [Full Text] [Related]

  • 32. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
    Gendron N, Belhouachi N, Morel V, Azgui Z, Maloum K, Nguyen-Khac F, Cayuela JM, Davi F, Merle-Béral H, Chapiro E.
    Ann Biol Clin (Paris); 2014 Jul 04; 72(3):359-66. PubMed ID: 24876147
    [Abstract] [Full Text] [Related]

  • 33. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K, Asagiri T, Kamioka M, Kojima K.
    Rinsho Ketsueki; 2021 Jul 04; 62(3):180-185. PubMed ID: 33828011
    [Abstract] [Full Text] [Related]

  • 34. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
    Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J.
    Blood; 2016 Mar 10; 127(10):1269-75. PubMed ID: 26729897
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.
    PLoS One; 2019 Mar 10; 14(3):e0207170. PubMed ID: 30835732
    [Abstract] [Full Text] [Related]

  • 37. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
    May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S, Genomics England Research Consortium, Willis F, Apperley JF, Innes AJ.
    BMC Med Genomics; 2023 Jul 26; 16(1):172. PubMed ID: 37496024
    [Abstract] [Full Text] [Related]

  • 38. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S.
    Acta Clin Belg; 2015 Aug 26; 70(4):237-43. PubMed ID: 26166681
    [Abstract] [Full Text] [Related]

  • 39. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP, Azevedo IF, Melo FCBC, Neves WB, Azevedo ACAC, Melo RAM.
    Genet Mol Res; 2017 Apr 20; 16(2):. PubMed ID: 28437552
    [Abstract] [Full Text] [Related]

  • 40. Are aberrant BCR--ABL transcripts more common than previously thought?
    Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, Reilly JT.
    Br J Haematol; 2000 Dec 20; 111(4):1109-11. PubMed ID: 11167748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.